One day after Bristol Myers Squibb announced the commercial launch of the multiple sclerosis drug Zeposia (ozanimod), the company said the medication demonstrated statistically significant efficacy as a potential induction and maintenance therapy for ulcerative colitis.
FDA Approves Eli Lilly’s Precision Oncology Treatment for Certain Lung and Thyroid Cancers
Accelerated Approval, Approvals, FDA, FDA/Regulatory, Metastatic Rearranged During Transfection (RET) Fusion-Positive Non-Small Cell Lung Cancer (NSCLC), New Drug Approvals, Precision Oncology, Product Launches, RET Kinase Inhibitors, Safety Warnings, Specialty Pharmacies, TumorsEli Lilly is moving quickly to get the newly approved precision oncology treatment Retevmo for certain lung and thyroid cancers into the hands of patients.
Although there were some deals announced at the ongoing J.P. Morgan Healthcare Conference, biotech stocks appeared to slide slightly at the overall lack of business transactions, at least during the first day or two.